DENVER – During November’s Lung Cancer Awareness Month, the International Association for the Study of Lung Cancer (IASLC) wants to highlight the importance of immunotherapy, a form of personalized medicine and a groundbreaking tool in the fight against lung cancer.

DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

DENVER – November is Lung Cancer Awareness Month, but lung cancer does not have an awareness problem; lung cancer has a perception problem. What many people believe about lung cancer is inaccurate, and the International Association for the Study of Lung Cancer (IASLC) knows that if we can confront these myths, we can change misconceptions and help find cures for lung cancer.

October 2015 Newsletter

The pace of progress in lung cancer is truly amazing and gratifying. In the last few weeks one immunotherapy drug was approved for lung cancer in the USA and another received an expanded indication. We have exciting data on the activity of these agents in small cell lung cancer and mesothelioma presented at the WCLC, and another new drug in small cell presented first there and advancing in clinical trials. New genetic targets are showing their impact on targeted therapies.

The IASLC APLCC meeting is soliciting bids for the APLCC IASLC conference in 2018. The APLCC IASLC conference is held every second year. Attendance is expected to range from 800 to 1,000 (including accompanying persons).

DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) recognizes the U.S. Food and Drug Administration’s (FDA) approval for another lung cancer immunotherapy agent (the second in two weeks) as a positive sign in the rapidly advancing science of lung cancer treatment. The last week the FDA approved nivolumab (Opdivo) to treat patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. This is an extended approval of the use for nivolumab, as it was approved in March 2015 for squamous NSCLC in the same setting.